<DOC>
	<DOCNO>NCT00768664</DOCNO>
	<brief_summary>This study investigate safety efficacy oral PF-00299804 patient yet undergone drug treatment recurrent and/ metastatic head neck squamous cell cancer .</brief_summary>
	<brief_title>Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Recurrent metastatic Squamous Cell Cancer Head Neck ; Measurable disease ; Eastern Cooperative Oncology Group ( ECOG ) 01 Stage 1 = first 23 patient ; Eastern Cooperative Oncology Group ( ECOG ) 02 Stage 2 = 33 patient ; prior therapy recurrence ; platelet &lt; 75,000 ; prior Epidermal Growth Factor Receptor ( EGFR ) therapy ; interstitial lung disease ; primary nasopharynx</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent metastatic squamous cell cancer Head Neck ; prior systemic therapy recurrence</keyword>
</DOC>